On February 6, 2018, the 50th participant enrolled in our ongoing Phase 1 study of the psychological effects of MDMA when used in a therapeutic setting by healthy volunteers. Enrollment in this multi-site study is limited by invitation only to therapists in training to work on MAPS-sponsored clinical trials of MDMA-assisted psychotherapy for PTSD. The Boulder, Colorado, study site is led by Principal Investigator Marcela Ot’alora, M.A., L.P.C. Michael Mithoefer, M.D., is serving as Principal Investigator at the site in Charleston, South Carolina with Sub-Investigator Ann Mithoefer, B.S.N. On February 15, 2018, Senior Clinical Research Associate Charlotte Harrison of MAPS Public Benefit Corporation (MPBC) traveled to Colorado for a monitoring visit of the study site in Boulder, which included a thorough review of the study’s documentation, database, files, and adherence to regulations. Learn more…
